Pristimerin-loaded nanoparticles enhance anti-neoplastic activity of platinum compounds
Endometrial cancer is the most frequent gynecological cancer and is often treated using platinum-based therapies such as cisplatin.
Unfortunately, tumors often develop resistance to cisplatin and related compounds, highlighting the need for novel antineoplastic therapies.
Inventors at the University of Iowa have discovered that a novel nanoparticle formulation of pristimerin markedly inhibits tumor growth when combined with cisplatin, by using patient-derived xenograft model of endometrial cancer. Further, pristimerin is an attractive molecule to combine with other platinum-based therapeutics for the treatment and prevention of drug resistant tumors.
- Patent Application No. PCT/US2020/038747
- Aliasger K. Salem, Department of Pharmaceutical Sciences and Experimental Therapeutics